Cargando…

BRCA1 mutation in the Triple- Negative Breast Cancer Group

Detalles Bibliográficos
Autores principales:	Maksimenko, Jelena, Irmejs, Arvids, Trofimovics, Genadijs, Miklasevics, Edvins
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518154/ http://dx.doi.org/10.1186/1897-4287-10-S4-A15

Ejemplares similares

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia
por: Plakhins, Grigorijs, et al.
Publicado: (2011)

Pregnancy after breast cancer in BRCA1/2 mutation carriers
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2023)

Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population
por: Hilz, Philip, et al.
Publicado: (2019)

Body mass index and nipple preservation are major contributors to satisfaction and aesthetic outcome rates after implant-based immediate breast reconstruction
por: Ukleikins, Stanislavs, et al.
Publicado: (2019)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Challenges in the management of a patient with Cowden syndrome: case report and literature review
por: Melbārde-Gorkuša, Inga, et al.
Publicado: (2012)

High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
por: Kalniete, Dagnija, et al.
Publicado: (2015)

Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Irmejs, Arvids, et al.
Publicado: (2008)

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
por: Berzina, Dace, et al.
Publicado: (2013)

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review
por: Loza, P., et al.
Publicado: (2021)

Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients
por: Berga-Švītiņa, Egija, et al.
Publicado: (2023)

Pilot Study on Low Penetrance Breast and Colorectal Cancer Predisposition Markers in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2006)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Population screening for hereditary and familial cancer syndromes in Valka district of Latvia
por: Vanags, Andrejs, et al.
Publicado: (2010)

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding
por: Irmejs, Arvids, et al.
Publicado: (2017)

Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia
por: Gardovskis, Andris, et al.
Publicado: (2005)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015
por: Thompson, Ella R., et al.
Publicado: (2017)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

BRCA1 mutation analysis in breast and ovarian cancer families from Greece
por: Konstantopoulou, I, et al.
Publicado: (2000)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
por: Johnson, SM, et al.
Publicado: (2000)

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
por: Sensi, E, et al.
Publicado: (2000)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

BRCA1 mutation- oncological treatment- reconstructive surgery of the breast- pregnancy: diagnostic and therapeutic procedures in a 28 year old patient diagnosed with a tumor in the left breast with a BRCA1 mutation
por: Kilar, Ewa
Publicado: (2012)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1bgffvi0ssmr8r71mf039kh41k